Briefcases -- ELIQUIS (apixaban) MDL 2754 USDC SD New York

ELIQUIS (apixaban) MDL 2754 USDC SD New York

Case Files
Summary
News
Committees
Request a Document
Search Within Briefcase

1/9/2019--UPDATE: Dismissal order entered on September 28, 2018 (per Mark Y.)

Eliquis is an oral anti-coagulant (blood thinner) made by Bristol-Myers and Pfizer, first put on the market in Europe in 2012 and then approved by the FDA in 2014 for use in the United States, and now the subject of litigation in Eliquis MDL 2734, case no. 16-MD-02754 in the US District Court, Southern District of New York. The clinical trials are alleged to have documented adverse effects including severe internal bleeding and other severe adverse symptoms including at least one death caused by Eliquis, which went unreported. Bristol-Myers and Pfizer chose to place Eliquis on the market while failing to disclose this critical information as required. Currently the claims in the MDL include wrongful death as well as ongoing severe medical injuries. Eliquis is another in the line of recent blood thinner products including Pradaxa and Xarelto that have been the subject of Multi-District Litigations, including drug maker Boehringer Ingelheim's $650 million settlement in 2014 to settle the Pradaxa MDL.  The recent Eliquis lawsuits center on patients who have died from internal bleeding or suffered other critical life altering injuries, including Deborah Herschell who's husband died after using Eliquis in June 2015 and Oliver Becker who suffered from atrial fibrillation (AFib) and also died after being prescribed Eliquis.